Hims & Hers: You Are Missing The Big Picture

Summary

  • Novo Nordisk just killed the deal. But Hims might come out even stronger. Here's why the market got it wrong.
  • GLP-1s are just the tip of the iceberg. Hims is quietly positioning itself as the gateway to the next wave of medical breakthroughs.
  • The stock plunged more than 40%, but our DCF shows it could be worth $70-plus. This might be the best buying opportunity yet.
  • From BPC-157 to increasing longevity, here’s the hidden pipeline that could make Hims the leader in performance, longevity, and mental health.
  • Looking for more investing ideas like this one? Get them exclusively at The Pragmatic Investor. Learn More »
Human Head with Open Window and Ladder on Grass and Sky Backdrop

Ekaterina Chizhevskaya/iStock via Getty Images

Thesis Summary

Hims & Hers (NYSE:HIMS) stock dropped after Novo Nordisk (NVO) announced the termination of its partnership with the company to sell its brand name GLP-1.

While this is a blow for Hims, I believe the current drop presents investors

Macro moves markets, and this is what I do at The Pragmatic Investor

Join today and enjoy:

- Weekly Macro Newsletter

- Access to our Portfolio

- Deep dive reports on stocks.

- Regular news updates

Start your free trial right now!

This article was written by

24.35K Followers

James Foord is an economist by trade and has been analyzing global markets for the past decade. He leads the investing group The Pragmatic Investor where the focus is on building robust and truly diversified portfolios that will continually preserve and increase wealth.

The Pragmatic Investor covers global macro, international equities, commodities, tech and cryptocurrencies and is designed to guide investors of all levels in their journey. Features include a The Pragmatic Investor Portfolio, weekly market update newsletter, actionable trades, technical analysis, and a chat room. Learn more.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of HIMS, NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About HIMS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on HIMS

Related Stocks

SymbolLast Price% Chg
HIMS
--